Lutathera for meningioma that grew after radiation and cannot be operated on
Tests Lutathera in adults with inoperable meningioma that progressed after radiation therapy.
Key facts
- Who runs it
- Mayo Clinic
- Where
- Rochester, United StatesSee the site
- Trial code
- Registry title
- Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 42 people, planned
- Started
- 14 Apr 2020
- Expected to end
- 4 Mar 2032
- Type of study
- Interventional
- Treatments tested
- Gallium Ga 68-DOTATATE
- Lutetium Lu 177 Dotatate
- Magnetic Resonance Imaging
- Positron Emission Tomography
- Questionnaire Administration
- Computed Tomography
- Biospecimen Collection
- Single Photon Emission Computed Tomography
- Record updated
- 13 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with meningioma that cannot be removed by surgery and keeps growing after radiation therapy. Grade I and grade II/III meningiomas can join.
- Age
- 18 Years and older
- Sex
- All sexes
- Disease stage
- Progressive meningioma that cannot be operated on, with measurable disease. Growth of 15% or more in about 6 months, or a new measurable lesion. No safe option for more radiation.
- Earlier treatment
- Must have had radiation therapy (fractionated or radiosurgery) at the growing tumor site, and surgery when possible. No somatostatin LAR within 4 weeks before joining.
- Biomarker or test result
- 68Ga-DOTATATE PET scan with a Krenning score of 2 or higher, showing somatostatin receptors on the tumor.
Main reasons for not taking part
- People who can still have surgery or radiation meant to remove all of the disease
- Pregnant or breastfeeding women, or people unwilling to use birth control
- Optic nerve sheath meningioma or meningioma outside the skull
- Other active cancer within 2 years, except some skin or cervical in-situ cancers
- Weak immune system, or HIV on antiretroviral therapy; unable to have MRI
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Previous treatment for meningioma including surgery, when possible, and radiation therapy (conventional fractionated or radiosurgery). Pathologic confirmation of meningioma is not required for patients who are not surgical candidates and received radiation therapy based on magnetic resonance imaging (MRI) consistent with meningioma. Patients with prior surgery will have pathologic confirmation of meningioma with either formalin-fixed paraffin-embedded (FFPE) tumor block OR meningioma tissue slides available for submission to central pathology review
- Radiographic evidence of meningioma progression with measurable disease, defined as an increase in size of the measurable primary lesion on imaging by 15% or more (sum of the bidirectional measurements) in an approximate 6 month time period (i.e., calculated rate of growth 15% / 6 months based on available scans) or by the appearance of a new measurable lesion
- Previous treatment with either fractionated radiation therapy or stereotactic radiosurgery at the site of progressive meningioma, without safe option for further radiotherapy
- Willing to undergo 68Ga-DOTATATE PET imaging. 68Ga-DOTATATE PET imaging must be Krenning score must be a score of 2 or higher, suggesting somatostatin receptor expression, to be registered on the study. A PET/MRI is preferred, but PET/CT is permitted if a patient is not technically able to receive a PET/MRI or at the discretion of the primary investigator (PI)
- Measurable disease
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) =< 2
- Absolute neutrophil count (ANC) >= 1500/mm (obtained =< 28 days prior to registration)
- Platelet count >= 100,000/mm (obtained =< 28 days prior to registration)
- Hemoglobin >= 9.0 g/dL (obtained =< 28 days prior to registration)
- Direct bilirubin < 1.5 x upper limit of normal (ULN) (or total bilirubin =< 3.0 x ULN with direct bilirubin =< 1.5 x ULN in patients with well-documented Gilbert's syndrome) (obtained =< 28 days prior to registration)
- Aspartate transaminase (AST) =< 3 x ULN (obtained =< 28 days prior to registration)
- Prothrombin time (PT)/international normalized ratio (INR)/partial thromboplastin time (PTT) =< 1.5 x ULN OR if patient is receiving anticoagulant therapy and PT or PTT is within therapeutic range of intended use of coagulants (obtained =< 28 days prior to registration)
- Calculated creatinine clearance must be >= 40 ml/min using the Cockcroft-Gault formula (obtained =< 28 days prior to registration) using the Chronic Kidney Disease Epidemiology Collaboration (CDK-EPI) equation
- Ability to complete questionnaire(s) by themselves or with assistance
- Provide written informed consent
- Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study) and it is highly recommend to see study staff in Radiation Oncology, Medical Oncology and/or Neuro-Oncology during the Event Monitoring Phase of the study
- Until 21 SPECT/CT slots are filled, willing to undergo SPECT/CT imaging for dosimetry analysis
Who cannot take part
- Eligibility for surgical or radiation treatment with curative intent
- Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:; Pregnant women (NOTE: Patients with surgical sterilization or who have been post-menopausal for at least 2 years are excluded form pregnancy testing, but this must be documented.); Nursing women; Men or women of childbearing potential who are unwilling to employ adequate contraception
- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
- Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
- Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm; Note: This includes treatment with somatostatin LAR within 4 weeks prior to enrollment, or any patient receiving treatment with short-acting octreotide that cannot be interrupted for greater than 24 hours before treatment
- Untreated, refractory and/or symptomatic toxicity related to previous radiation therapy including radiation necrosis, radiation optic neuropathy, or radiation retinopathy
- History of myocardial infarction =< 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association [NYHA] II, III, IV), unstable angina pectoris, uncontrolled diabetes mellitus (fasting blood glucose > 2 ULN), cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Other active malignancy =< 2 years prior to registration; EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix; NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer
- Contraindications to or intolerance of MRI
- Current spontaneous urinary incontinence making impossible the safe administration of LUTATHERA
- Optic nerve sheath meningioma, extracranial meningioma
Where in United States
- Mayo Clinic in RochesterRochester, United StatesContact: Clinical Trials Referral OfficeTaking people
About the trial
What the trial wants to find out
This phase II trial studies how well lutathera works in treating patients with meningioma that cannot be treated with surgery (inoperable) and is growing, spreading, or getting worse (progressive) after external beam radiation therapy. Lutathera is a radioactive drug administered in the vein that is designed to target and kill tumor cells. The goal of this study is to determine whether this drug is safe and effective in treating meningiomas that progress after radiation treatment. WHO Grade I and Cohort WHO II/III cohorts will be evaluated.
The group in the trial
- Treatment (gallium Ga 68-DOTATATE PET/MRI, Lutathera)Treatment being tested
Patients receive gallium Ga 68-DOTATATE IV and undergo a PET/MRI or PET/CT before cycles 1 and 4. Patients then receive lutetium Lu 177 dotatate IV over 30-40 minutes. Treatment repeats every 8 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo MRI on study and during follow-up, as well as blood sample collection and possible SPECT/CT dosimetry on study.
Treatment: Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Computed Tomography, Biospecimen Collection, and Single Photon Emission Computed Tomography
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Prospective, Phase II Study of Lutetium Lu 177 Dotatate (LUTATHERA®) in Patients With Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- Plain-language title
- Lutathera for meningioma that grew after radiation and cannot be operated onGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 13 October 2026